本文轉載自原廠電子報:Akron Biotech | www.akronbiotech.com
|
Our cGMP Cytokine Portfolio
|
|
We hope your year is off to a good start. At Akron Biotech, we’ve been busy—manufacturing cGMP ancillary materials, growing our team, developing our product lines, and collaborating on exciting developments in regenerative medicine. We have a number of upcoming events, and we can’t wait to connect with you.
Read on.
|
|
Spotlight: cGMP Recombinant Cytokines and Growth Factors
|
|
The quality of cytokines and growth factors is critical to a cell or gene therapy’s ultimate success. At Akron, we take an orthogonal approach to protein purification, which ultimately produces clean, high-quality proteins.
Our cGMP cytokines feature:
· Batch-to-batch consistency
· ISO-Certified cGMP production with quality-controlled materials
· eCTD DMFs (Drug Master Files)
· Lyophilized vials or liquid formulation in syringes
· Available at commercial scale
Take a look at our cGMP recombinant cytokine and growth factor portfolio.
|
|
|
In the rapidly developing industry of advanced therapies, the quality and consistency of ancillary materials take center stage when considering the drug manufacturer’s cost control and the ultimate quality of the end therapy.
It is our responsibility as ancillary suppliers to take the initial steps in reducing the inherent variability within our industry. Find out some of the ways Akron measures variation in cytokines.
|
|
|
|
|
March 3 @ 8pm ET
USP-APEC Center of Excellence for Advanced Therapies Pilot Virtual Workshop
Dr. Claudia Zylberberg, Chief Executive Officer, will speak at this USP-APEC Workshop on raw materials for advanced therapies, in a talk titled, “Selection and sourcing of materials.”
Details
|
|
|
|
March 11 @ 1pm ET
XTalks Webinar: De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products
Akron Biotech Vice President of Global Sales Robert Margolin, SCB President and ARMI Chief Regulatory Officer Richard McFarland, and Adaptimmune Associate Director of Process Sciences Raymond Luke will discuss strategies for how to ensure the integrity of ancillary materials in the manufacture of advanced therapy products.
Details
|
|
|
|
|
|
March 23-25
Innate Killer Summit
2020 has been a game-changing year for the NK cell community. Join us at the 2021 Innate Killer Summit to discuss the latest findings and approaches.
Details
|
|
|
|
April 6-9
ARM | Cell and Gene Meeting on the Med
Connect with our sales team at the virtual Meeting on the Med. Also, David Smith, President and Chief Commercial Officer, will discuss Akron Biotech’s mission, company history, latest developments.
Details
|
|
|
|
|
|
|
